Schizophrenia: all 3,539 studies

Page 20 of 36. Open to participants first (473), then studies with results posted, then the rest; newest registration first within each.

• A Clinical Study to Evaluate the Bioavailability Between Two Products Containing Paliperidone 100 mg in the Form of a Prolonged Release Suspension for Injection in Patients With Schizophrenia Who Are Already Stabilized in This TreatmentCompletedNCT03425552Phase 1/2
• Adjunctive Selective Estrogen Receptor Modulators on Negative and Cognitive Symptoms of Schizophrenia in WomenCompletedNCT03418831Phase 4
• Gut Microbiome in AP NaiveActive, not recruitingNCT03414151
• rTMS Treatment for Positive and Negative Symptoms of SchizophreniaStatus unknownNCT03413527Phase 2/3
• Feasibility and Relevance of High-Intensity Functional Training in Patients With First-Episode PsychosisCompletedNCT03409393Not applicable
• The Application of Wearable Technology to Improve the Physical Activity Level of People With Chronic Mental IllnessCompletedNCT03408327Not applicable
• Cognitive Remediation Program for Hospitalized in the Long Term Patients With Deficit SchizophreniaWithdrawnNCT03407950Not applicable
• Peer Support Experience for Patients Discharged From Acute Psychiatric CareCompletedNCT03404882Not applicable
• A Study of Lurasidone HCl in Subjects With SchizophreniaCompletedNCT03393026Phase 4
• Mirror-image Study of Paliperidone Palmitate and Risperidone Long-acting InjectionStatus unknownNCT03390712
• OnTrack>An Online Role-Playing Game for Young People With First Episode PsychosisCompletedNCT03390491Not applicable
• The Effects of tDCS on Auditory Hallucination, Insight, Neurocognitive Function and HRV in Patients With SchizophreniaCompletedNCT03388554Not applicable
• Abilify Maintena PMS in Schizophrenia Patients or Bipolar 1 DisorderCompletedNCT03386851
• A 12-weeks Study to Evaluate the Dietary Fiber and Probiotics Treatment in Prevention and Intervention of Weight-gain and Cognitive Impairment of Schizophrenia or Bipolar DisorderCompletedNCT03379597Not applicable
• Study on Examination of Therapeutic Efficacy and Potential Mechanisms of Yoga Treatment in SchizophreniaCompletedNCT03379480Not applicable
• MAintain the Efficacy and Safety in Treatment of Schizophrenia After Switching to Long-acTing Injectable aRipiprazole From Oral Atypical AntipsychoticsCompletedNCT03376763Phase 4
• Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Japanese Male and Female Subjects With Schizophrenia in 2 Parts (Part 1 and 2).CompletedNCT03370640Phase 1
• Add-on Methotrexate for the Treatment of SchizophreniaStatus unknownNCT03369795Phase 2
• A Study to Assess the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of ASP6981 in Subjects With SchizophreniaCompletedNCT03356639Phase 1
• Childhood Trauma in Schizophrenia: Exploration of Links Between Gene Expression, Cerebral Morphology and SymptomatologyCompletedNCT03355781
• Examining Persistence in Smokers With SchizophreniaCompletedNCT03346291Not applicable
• The Norwegian Prednisolone in Early Psychosis StudyTerminatedNCT03340909Phase 2
• Evaluation of Metamemory in Patients With SchizophreniaCompletedNCT03338179Not applicable
• Pharmacokinetics and Safety Studies of Esomeprazole Use in Schizophrenia PatientsCompletedNCT03333603Phase 4
• Mindfulness and Cognition in SchizophreniaTerminatedNCT03318640Not applicable
• Creating Live Interactions to Mitigate BarriersCompletedNCT03317769Not applicable
• Assessment of Efficacy of a Psychological Therapy in Inpatients With a Schizophrenic PsychosisCompletedNCT03316664Not applicable
• Remediation of Visual Perceptual Impairments in People With SchizophreniaCompletedNCT03314129Not applicable
• Effectiveness of a Mindfulness-based Group Training Addressing Social Cognition in First Episode Psychosis (AGES-Mind)CompletedNCT03309475Not applicable
• Lurasidone Vs Olanzapine on Neurotrophic Biomarkers and Cardiometabolic Parameters in Unmedicated SchizophreniaCompletedNCT03304457Phase 4
• A Research in Pharmacogenomics and Accurate Medication of RisperidoneStatus unknownNCT03302364
• Influence of Environmental Factors and SchizophreniaStatus unknownNCT03296384Not applicable
• Pharmacologic Treatment of Acute Episode of Schizophrenia: a Real World StudyCompletedNCT03289026Phase 4
• Aripiprazole IM Depot for Chinese Patients With SchizophreniaCompletedNCT03287505Phase 1
• PK Study of Aripiprazole IM Depot for Chinese Patients With SchizophreniaCompletedNCT03285503Phase 1
• Influence of Vitamin D Supplementation on Serum BDNF Level and Cognitive Function in SchizophreniaStatus unknownNCT03284294Phase 3
• Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of First Rank Symptoms (FRS) on SchizophreniaCompletedNCT03284138Not applicable
• Effects of a Psycho-corporal Training on Postural and Cognitive Dual-task Performances in Patients With SchizophreniaCompletedNCT03280810Not applicable
• Integrated Psychological Therapy for Chronic SchizophreniaCompletedNCT03275909Not applicable
• Integrated Supported Employment in Mainland ChinaCompletedNCT03273530Not applicable
• A Study of rTMS for Cognitive Deficits in Chronic Patients With SchizophreniaCompletedNCT03273439Not applicable
• Metformin Treatment on Cognitive Impairment of Schizophrenia Co-morbid Metabolic SyndromeStatus unknownNCT03271866Not applicable
• Brain Biomarker on Inflammation ResponseWithdrawnNCT03271814Phase 1
• Improving Cognition Via Exercise in SchizophreniaCompletedNCT03270098Not applicable
• HDAC Inhibitor Augmentation to ClozapineWithdrawnNCT03263533Early Phase 1
• A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic DisordersTerminatedNCT03261817Not applicable
• Cognitive Behavioral Social Skills Training in Early Onset PsychosisCompletedNCT03261557Not applicable
• A Neurofeedback Intervention to Improve Working Memory in SchizophreniaCompletedNCT03260257Not applicable
• Positron Emission Tomography (PET) Imaging of Glial Activation in Psychotic Disease StatesTerminatedNCT03257592Phase 1
• Phenomics and Genomics of Clozapine PharmacotherapyStatus unknownNCT03253367
• Berberine Treat Metabolic Syndrome in SchizophreniaCompletedNCT03251716Not applicable
• Peer-led Psycho-education for SchizophreniaCompletedNCT03246932Not applicable
• Target Engagement and Response to OxytocinCompletedNCT03245437Phase 4
• Joint Crisis Plans or Crisis Cards for People With Severe Mental Disorders to Reduce Coercion in Psychiatric Care.Status unknownNCT03240380Not applicable
• Validating and Optimizing Model of Antipsychotics SelectionStatus unknownNCT03237052Not applicable
• Copeptin in Outcome Prediction of an Acute Psychotic EpisodeCompletedNCT03235908
• Study on Communication Comprehension in the Schizophrenic SpectrumCompletedNCT03225027Not applicable
• Influence of Amphetamine-induced Sensitization on Dopamine Synthesis and ReleaseStatus unknownNCT03223844Not applicable
• Cognitive Behavioural Therapy- Social Functioning In Adolescence With Recent Onset SchizophreniaCompletedNCT03217955Not applicable
• tDCS, Stress and Risk for SchizophreniaCompletedNCT03217357Not applicable
• Neurostimulation-enhanced Behavioral Remediation of Social Cognition in SchizophreniaWithdrawnNCT03213600Not applicable
• Involuntary Memories Investigation in SchizophreniaTerminatedNCT03209778Not applicable
• Social Isolation and Loneliness in Older PeopleStatus unknownNCT03201731
• Development of a Mobile Heath Augmented Brief Suicide Prevention Intervention for People With SMICompletedNCT03198364Not applicable
• Psychosocial Intervention to Reduce Self-stigma and Improve Quality of Life Among People With Mental Illness in ChileCompletedNCT03197168Not applicable
• Financial Incentives to Improve Acceptance of Antipsychotic InjectionsStatus unknownNCT03192631Not applicable
• Music to Reduce Use of Smoking in Patients With SchizophreniaCompletedNCT03190161Not applicable
• Effects of Repetitive Transcranial Magnetic Stimulation (rTMS) on Cannabis Use and Cognitive Outcomes in SchizophreniaCompletedNCT03189810Not applicable
• Visual Information Processing in Schizophrenia Patients With Visual HallucinationsStatus unknownNCT03188133Not applicable
• Symptom Based Treatment Affects Brain Plasticity - Cognitive Training in Patients With Affective SymptomsCompletedNCT03183947Not applicable
• Confirmatory Efficacy Trial of a Gluten-Free Diet in a Subgroup of Persons With Schizophrenia Who Have High Levels of IgG Anti-Gliadin Antibodies (AGA IG)CompletedNCT03183609Not applicable
• Mobile-Assisted Cognitive Behavior Therapy for Negative Symptoms in SchizophreniaCompletedNCT03179696Not applicable
• The Evaluation of the Use of a New Physical Health PlanCompletedNCT03178279Not applicable
• Aripiprazole IM Depot in the Acute Treatment of Adults With SchizophreniaCompletedNCT03172871Phase 3
• The Role of Dysmyelination in Cognitive Impairment of Psychotic Spectrum DisordersCompletedNCT03166098
• Safety, Tolerability and Pharmacokinetics of AUT00206 in Patients With Schizophrenia, and Also Explores the Effects of AUT00206 on Relevant Central Biomarkers.CompletedNCT03164876Phase 1
• Evaluation of Stroop Effect in Patients With SchizophreniaStatus unknownNCT03163706Not applicable
• The Effects of Prebiotics on Cognitive Functioning and Weight Gain in PsychosisCompletedNCT03153046Not applicable
• Employment Outcomes After Vocational TrainingCompletedNCT03152032Not applicable
• Study to Determine the Pharmacokinetics, Safety & Tolerability of Aripiprazole in Adults With SchizophreniaCompletedNCT03150771Phase 1
• "Multimodal Prevention of Psychosis - Investigating Efficacy of N-Acetylcysteine and Psychotherapy in CHR-Patients"TerminatedNCT03149107Phase 3
• Virtual Reality Therapy for Treatment-resistant Auditory Hallucinations in SchizophreniaCompletedNCT03148639Not applicable
• Evaluation of Executive Function With Virtual Reality Among People With SchizophreniaStatus unknownNCT03146364Not applicable
• Mindfulness Group-based Intervention for Early PsychosisCompletedNCT03143907Not applicable
• Explorations of the Normal Neural Behavioral and Pathological Bases of MetacognitionCompletedNCT03140475
• Video Games Among People With SchizophreniaCompletedNCT03133143Not applicable
• INCLUDE: Using Lived Experience to Improve Mental Health Diagnosis v1CompletedNCT03131505
• Predictors of Persistence in Patients With Schizophrenia Treated With Once-monthly Aripiprazole in SpainCompletedNCT03130478
• Aripiprazole Once-monthly Versus Daily Oral Atypical Antipsychotic Treatment in Patients With Recent-onset SchizophreniaStatus unknownNCT03130465
• Evaluation of a Visual Remediation Intervention for SchizophreniaStatus unknownNCT03117452Not applicable
• Role of Vitamin D Supplementation in SchizophreniaCompletedNCT03101319Not applicable
• Inflammatory Response In SchizophreniaCompletedNCT03093064Phase 1
• Procedures for Sample Acquisition and Distribution for The Human Brain Collection CoreTerminatedNCT03092687
• Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: 3-year Follow-upStatus unknownNCT03090503Phase 4
• 10-year Follow-up of Clinical Outcome After Antipsychotic Treatment Discontinuation in Psychosis IndividualsStatus unknownNCT03090490Not applicable
• The Effect of a Community-based LAI-treated Management Model on the Violence Risk of Patients With SchizophreniaStatus unknownNCT03080194Phase 4
• Neural Biomarkers of Clozapine ResponseCompletedNCT03076346
• Integration of Illness Management and Recovery Within ACTCompletedNCT03075800Not applicable
• Study of add-on Ramelteon Therapy on Sleep and Circadian Rhythm Disruption in Patients With SchizophreniaCompletedNCT03075657Phase 4
• Role of an E-cigarette on Smoking Displacement in Smokers With SchizophreniaCompletedNCT03075202

← Schizophrenia overview